234 related articles for article (PubMed ID: 36281556)
21. Identification and validation of an immune prognostic signature in colorectal cancer.
Li M; Wang H; Li W; Peng Y; Xu F; Shang J; Dong S; Bu L; Wang H; Wei W; Hu Q; Liu L; Zhao Q
Int Immunopharmacol; 2020 Nov; 88():106868. PubMed ID: 32771948
[TBL] [Abstract][Full Text] [Related]
22. B7-H4 is a potential diagnostic and prognostic biomarker in colorectal cancer and correlates with the epithelial-mesenchymal transition.
Yan X; Hong B; Feng J; Jin Y; Chen M; Li F; Qian Y
BMC Cancer; 2022 Oct; 22(1):1053. PubMed ID: 36217128
[TBL] [Abstract][Full Text] [Related]
23. Topoisomerase IIβ binding protein 1 serves as a novel prognostic biomarker for stage II-III colorectal cancer patients.
Wang Y; Yan X; Qu X; Mao J; Wang J; Yang M; Tao M
Pathol Res Pract; 2023 Jan; 241():154287. PubMed ID: 36586311
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of m6A-GPI signatures as a novel prognostic model for colorectal cancer.
Ma B; Bao S; Li Y
Front Oncol; 2023; 13():1145753. PubMed ID: 37427112
[TBL] [Abstract][Full Text] [Related]
25. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
Jiao J; Jiang L; Luo Y
Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
[TBL] [Abstract][Full Text] [Related]
26. Gene Alterations of N6-Methyladenosine (m
Zhang Q; Cai Y; Kurbatov V; Khan SA; Lu L; Zhang Y; Johnson CH
Biomed Res Int; 2020; 2020():8826456. PubMed ID: 33415160
[TBL] [Abstract][Full Text] [Related]
27. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer.
Matsuyama T; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kawano T; Uetake H; Goel A
Mol Cancer; 2019 Feb; 18(1):19. PubMed ID: 30717807
[TBL] [Abstract][Full Text] [Related]
28. Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer.
Wang D; Liufu J; Yang Q; Dai S; Wang J; Xie B
Biol Direct; 2022 Nov; 17(1):29. PubMed ID: 36319976
[TBL] [Abstract][Full Text] [Related]
29. Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients.
Wang JM; Li X; Yang P; Geng WB; Wang XY
BMC Gastroenterol; 2022 Feb; 22(1):76. PubMed ID: 35189810
[TBL] [Abstract][Full Text] [Related]
30. Construction of an N6-methyladenosine lncRNA- and immune cell infiltration-related prognostic model in colorectal cancer.
Yu ZL; Zhu ZM
Protoplasma; 2022 Jul; 259(4):1029-1045. PubMed ID: 34734333
[TBL] [Abstract][Full Text] [Related]
31. Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes.
Wang K; Song K; Ma Z; Yao Y; Liu C; Yang J; Xiao H; Zhang J; Zhang Y; Zhao W
Br J Cancer; 2020 Aug; 123(3):410-417. PubMed ID: 32435058
[TBL] [Abstract][Full Text] [Related]
32. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel lymphangiogenesis signature associated with immune cell infiltration in colorectal cancer based on bioinformatics analysis.
Liu H; Shi H; Sun Y
BMC Med Genomics; 2024 Jan; 17(1):2. PubMed ID: 38167072
[TBL] [Abstract][Full Text] [Related]
34. Identification and verification of m6A-related miRNAs correlated with prognosis and immune microenvironment in colorectal cancer.
Qiu X; Chen D; Huang S; Chen N; Wu J; Liang S; Peng P; Qin M; Huang J; Liu S
Medicine (Baltimore); 2023 Nov; 102(46):e35984. PubMed ID: 37986290
[TBL] [Abstract][Full Text] [Related]
35. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
Front Oncol; 2021; 11():710767. PubMed ID: 34458149
[TBL] [Abstract][Full Text] [Related]
36. Construction and validation of a novel prognostic model for lung squamous cell cancer based on N6-methyladenosine-related genes.
Jia E; Ren N; Guo B; Cui Z; Zhang B; Xue J
World J Surg Oncol; 2022 Feb; 20(1):59. PubMed ID: 35220962
[TBL] [Abstract][Full Text] [Related]
37. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.
Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J
Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955
[TBL] [Abstract][Full Text] [Related]
38. Identification of a five m6A-relevant mRNAs signature and risk score for the prognostication of gastric cancer.
Yin L; Feng S; Sun Y; Jiang Y; Tang C; Sun D
J Gastrointest Oncol; 2022 Oct; 13(5):2234-2248. PubMed ID: 36388685
[TBL] [Abstract][Full Text] [Related]
39. Identification of N6-methylandenosine related lncRNA signatures for predicting the prognosis and therapy response in colorectal cancer patients.
Li Z; Liu Y; Yi H; Cai T; Wei Y
Front Genet; 2022; 13():947747. PubMed ID: 36246627
[TBL] [Abstract][Full Text] [Related]
40. N6-Methyladenosine-Related lncRNAs Are Potential Prognostic Biomarkers and Correlated With Tumor Immune Microenvironment in Osteosarcoma.
Zheng D; Yu L; Wei Z; Xia K; Guo W
Front Genet; 2021; 12():805607. PubMed ID: 35186011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
